# Sildenafil in COVID-19

> **NCT04489446** · PHASE1,PHASE2 · COMPLETED · sponsor: **Universidad Nacional Andres Bello** · enrollment: 40 (actual)

## Conditions studied

- Covid19
- SARS-COV2 Infection

## Interventions

- **DRUG:** Sildenafil
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04489446
- **Lead sponsor:** Universidad Nacional Andres Bello
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-19
- **Primary completion:** 2021-04-30
- **Final completion:** 2021-06-30
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2021-09-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04489446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04489446, "Sildenafil in COVID-19". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04489446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*